Land: Bretland
Tungumál: enska
Heimild: MHRA (Medicines & Healthcare Products Regulatory Agency)
Chloroquine phosphate
Wallace Manufacturing Chemists Ltd
P01BA01
Chloroquine phosphate
16mg/1ml
Oral solution
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05040100; GTIN: 05034593034406
Malarivon Syrup 50mg in 5ml (as base) Oral Solution Chloroquine Phosphate _Read all of this leaflet carefully before you start using this medicine because it contains important information for you._ _ _ ✧_ Keep this leaflet. You may need to read it again_ _ _ ✧_ If you have any further questions, ask your doctor or pharmacist_ _ _ ✧_ This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness or risk of contracting malaria are the same as yours_ _ _ ✧_ If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4._ IN THIS LEAFLET 1. What is Malarivon Syrup and what is it used for? 2. What you need to know before you use Malarivon Syrup? 3. How to use Malarivon Syrup? 4. Possible side effects? 5. How to store Malarivon Syrup? 6. Contents of the pack and other information. 1. What is Malarivon Syrup and what is it used for? Malarivon Syrup contains chloroquine phosphate and belongs to a group of medicines called ‘anti- malarials’. It acts on the malarial parasite in the blood stream, and may prevent, suppress or treat the disease depending upon the strain of parasite contracted and the progression of the disease. You must get medical advice on which anti-malarial medicine to take. When travelling to an area where there is a risk of contracting malaria always consult official guidelines and local information before deciding on which preventative treatment to take. No treatment to prevent malaria is 100% effective. 2. What you need to know before you use Malarivon Syrup? DO NOT USE: ✦ If you are allergic (hypersensitive) to chloroquine phosphate or any of the ingredients listed in section 6 of this leaflet ✦ If you are taking a medicine called amiodarone (used to control the heart rate). Malarivon Syrup may increase the risk of uneven heart beats (cardiac arrhythmias) when it is taken at the same time as amiodarone. WARNINGS AND PRECAUTIONS Talk to your Lestu allt skjalið
OBJECT 1 MALARIVON SYRUP Summary of Product Characteristics Updated 06-Jan-2017 | Wallace Manufacturing Chemists Ltd 1. Name of the medicinal product Malarivon Syrup 2. Qualitative and quantitative composition Each 5ml contains: Chloroquine Phosphate 80.0mg equivalent to Chloroquine base 50.0mg Excipient(s) with known effect: Sucrose Methyl, Ethyl, Propyl and Butyl Hydroxybenzoic Acid Esters Propylene Glycol Colouring (Ponceau 4R) E124 For the full list of excipients, see section 6.1. 3. Pharmaceutical form Solution 4. Clinical particulars 4.1 Therapeutic indications For the prophylaxis, suppression and treatment of malaria. 4.2 Posology and method of administration Method of administration Oral Posology TABLE 1 Age Group Dose Children up to 1 year: 2.5-5ml 1 to 3 years: 7.5-10ml 3 to 6 years: 10-15ml 6 to 9 years: 15-22.5ml 9 to 12 years: 22.5-30ml Adults: 30ml PROPHYLAXIS OR SUPPRESSION OF MALARIA, NON-IMMUNE A single weekly dose, as shown in Table 1, beginning two weeks before and continuing four weeks after exposure to infection PROPHYLAXIS OR SUPPRESSION OF MALARIA, PARTIALLY-IMMUNE Half the dose in table 1 every two weeks will afford a high degree of protection. TREATMENT OF MALARIA, NON-IMMUNE Give twice the dose in Table 1, then give the same dose as in table 1 six hours later and then once a day for two days. TREATMENT OF MALARIA, PARTIALLY IMMUNE Give twice the dose in table 1 once only No distinction is made between the dose for adults and the elderly. 4.3 Contraindications Hypersensitivity to chloroquine or to any of the excipients listed in section 6.1 Concomitent use with amiodarone. (See section 4.5) 4.4 Special warnings and precautions for use When used as malaria prophylaxis official guidelines and local information on prevalence of resistance to anti-malarial drugs should be taken into consideration. Irreversible retinal damage and corneal changes may develop during long term therapy and after the drug has been discontinued. Ophthalmic examination prior to, and at 3-6 monthly intervals during us Lestu allt skjalið